Lyra Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
Sabby Management, LLC and affiliated entities reported a 9.9% beneficial ownership stake in Lyra Therapeutics, Inc. common stock.
OTC.Pink
SCHEDULE 13G/A: Citadel Entities Update Passive Stake in Lyra Therapeutics, Reporting 0.0% Beneficial Ownership
Citadel and its affiliated entities have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 0.0% in Lyra Therapeutics, Inc. as of December 31, 2024.